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Objective: A prospective clinical study was designed to assess the frequency and
severity of intravascular hemolysis in patients with new-generation, normally func-
tioning prosthetic heart valves.
Methods: Hemolysis was evaluated in 172 patients with a mechanical prosthesis (53
CarboMedics and 119 Sorin Bicarbon) and in 106 patients with a bioprosthesis (15
St Jude Medical Toronto, 19 Baxter Perimount, and 72 Medtronic Mosaic) in the
aortic position, mitral position, or both. Aortic valve replacement was performed in
206 patients, mitral valve replacement in 59 patients, and double valve replacement
in 13 patients. The presence of hemolysis was assessed on the basis of the level of
serum lactic dehydrogenase and serum haptoglobin and the presence and amount of
reticulocytes and schistocytes in the peripheral blood. Severity of intravascular
hemolysis was estimated on the basis of serum lactic dehydrogenase. Clinical,
echocardiographic, and hematologic evaluations were performed 1, 6, and 12
months after discharge.
Results: None of the 278 patients experienced decompensated anemia, whereas at
12 months, mild subclinical hemolysis was identified in 49 patients, 44 (26%) with
a mechanical prosthesis and 5 (5%) with a bioprosthesis (P < .001). At multivariate
analysis, independent predictors of the presence of subclinical hemolysis were
mitral valve replacement (P < .001), use of a mechanical prosthesis (P = .002), and
double valve replacement (P = .02). Frequency of hemolysis in patients with stented
aortic bioprostheses was 3%, whereas it was absent in those with stentless valves.
Among mechanical valve recipients, double versus single valve replacement (P =
.04) and mitral versus aortic valve replacement (P = .05) were correlated with the
presence of hemolysis; double valve recipients also showed a more severe degree of
hemolysis (P = .03). In patients with a Sorin Bicarbon prosthesis, hemolysis was
less frequent (22% vs 34%, P = .09) and severe (P < .001) than in those with a
CarboMedics prosthesis.
Conclusions: In normally functioning prosthetic heart valves, subclinical hemolysis
is a frequent finding. A low incidence of hemolysis is found in stented biologic
prostheses, and it is absent in stentless aortic valves. Modifications of valve design
may contribute to minimize the occurrence of hemolysis in mechanical prostheses.
Since the implantation of the first mechanical prosthesis by Hufnagel in1956,1 traumatic hemolysis has been recognized as a potentially seri-ous problem after heart valve replacement. This complication, reportedto occur in 5% to 15% of patients with a ball-caged valve, is rarelyobserved with current normally functioning prostheses but is stillencountered in the setting of prosthetic valve dysfunction and regurgi-
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tation.2,3 However, it has been demonstrated that chronic
subclinical hemolysis may be present in patients with
mechanical or biologic valve prostheses.4-6 Turbulence of
flow with high shear-stress forces and abnormal flow jets
through the prosthetic valve are thought to be causes of
hemolysis.7-9 Accordingly, modifications of valve design
may contribute to the minimization of the occurrence of
such complications by enhancing hemodynamic perform-
ance. The aim of this study was to evaluate prospectively
the presence of hemolysis in patients with new-generation
prosthetic valves and to correlate the frequency and severity
of hemolysis to prosthesis number, type, size, and position.
Materials and Methods
Patient Population
From January 1997 to December 1998, a total of 434 patients who
underwent mitral valve replacement (MVR), aortic valve replace-
ment (AVR), or both were discharged with normally functioning
prosthetic valves. Patients with renal, hepatic, or pulmonary dis-
ease were excluded from the study. Informed consent to be
enrolled in this study was obtained from 300 patients. However, a
complete set of clinical, hematologic, and echocardiographic
assessments was available for only 280 of them. Two patients
showing paraprosthetic leak at follow-up echocardiography were
removed from the study, and the remaining 278 patients form the
basis of the present report.
There were 157 men and 121 women, with a mean age of 67 ±
9 years (range, 27-86 years). The main preoperative characteristics
are summarized in Table 1.
AVR was performed in 206 (74%) patients, MVR was per-
formed in 59 (21%) patients, and MVR plus AVR (double valve
replacement [DVR]) was performed in 13 (5%) patients. For AVR,
a mechanical prosthesis was used in 113 (41%) patients, and a bio-
prosthesis was used in 93 (33%) patients. MVR was performed
with a mechanical prosthesis in 46 (17%) patients and with a bio-
prosthesis in 13 (5%) patients. All patients with DVR received
mechanical prostheses. A total of 291 prostheses were implanted:
53 CarboMedics (CM; Sulzer Carbomedics, Inc, Austin, Tex), 119
Sorin Bicarbon (SB; Sorin Biomedica Spa, Saluggia, Italy), 15 St
Jude Medical Toronto stentless (St Jude Medical, Inc, St Paul,
Minn), 19 Baxter Perimount (Baxter Healthcare Corp, Edwards
Division, Santa Ana, Calif), and 72 Medtronic Mosaic (Medtronic,
Inc, Minneapolis, Minn) prostheses. All patients were receiving
oral anticoagulant therapy with warfarin for 3 months after the
operation. Thereafter, only patients with a mechanical prosthesis or
those in chronic atrial fibrillation continued oral anticoagulation.
Study Protocol
Patients were evaluated preoperatively and postoperatively at 1, 6,
and 12 months. Every follow-up examination consisted of (1) clin-
ical evaluation with investigation for other possible causes of
hemolytic anemia, (2) assessment of prosthetic valve function by
means of transthoracic or transesophageal echocardiography, and
(3) hematologic evaluation of hemolysis, as measured by total
blood hemoglobin level, serum lactic dehydrogenase (LDH) level,
serum haptoglobin level, reticulocyte count, and presence of schis-
tocytes on a peripheral blood smear. All tests were performed in
the same laboratory.
Criteria for Hemolysis
As suggested by Skoularigis and colleagues,10 patients were consid-
ered to have intravascular hemolysis under the following conditions:
1. Serum LDH levels were greater than 460 U/L (normal, 230-
460 U/L).
2. Any 2 of the following 4 criteria were present: (1) blood hemo-
globin level of less than 13.8 g/dL for male patients (normal,
13.8-17.9 g/dL) and less than 12.4 g/dL for female patients
(normal, 12.4-15.5 g/dL); (2) serum haptoglobin levels of less
than 0.5 g/L (normal, 0.5-3.2 g/L); (3) reticulocyte count of
greater than 2% (normal, <2%); or (4) presence of schistocytes
in the peripheral blood smear (normally absent).
Frequency of hemolysis has been reported only at 12 months.
Severity of intravascular hemolysis was estimated on the basis of
serum LDH levels at 12 months.
Statistical Analysis
Data are presented as means ± SD and as simple percentages. A
separate analysis was performed to identify the variables associ-
ated with the presence of subclinical hemolysis in the overall pop-
ulation, in aortic valve recipients, in mitral valve recipients, in
mechanical valve recipients, and in bioprosthesis recipients. The
variables analyzed were the following: sex; age; heart rhythm; use
of mechanical or biologic prosthesis; prosthetic model, size, and
site of implantation; single valve replacement or DVR; aortic and
mitral peak and mean transprosthetic gradients; and left ventricu-
lar ejection fraction. Univariate analysis was performed with the
χ2 test or the Fisher test, as appropriate, for discrete variables and
with the paired t test or the Mann-Wilcoxon test for continuous
TABLE 1. Patient characteristics
No. of patients 278
Sex (M/F) 157/121
Age (y) 67 ± 9
NYHA class 2.5 ± 0.7
Sinus rhythm 232 (83%)
Atrial fibrillation 35 (13%)
Pacemaker 11 (4%)
Left ventricular ejection fraction (%) 51 ± 10
LDH (U/L) 357 ± 123
Haptoglobin (g/L) 1.8 ± 1.2
Hemoglobin (g/dL) 12.9 ± 1.6
Reticulocytes 1.6 ± 0.4
AVR 206 (74%)
Mechanical 113 (41%)
Biologic 93 (33%)
MVR 59 (21%)
Mechanical 46 (17%)
Biologic 13 (5%)
DVR 13 (5%)
Mechanical 13 (5%)
NYHA, New York Heart Association.
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variables. All parameters showing a P value of less than .10 at uni-
variate analysis were introduced in a stepwise logistic regression
for multivariate analysis. Only variables associated with hemoly-
sis with P values of less than .20 at univariate or multivariate
analysis were reported in Table 2.
Repeated-measures analysis of variance (ANOVA) with the
Bonferroni multiple comparison test was used to assess the influ-
ence of time on serum LDH and haptoglobin levels. The α value for
the Bonferroni test was set at .05. Statistical analysis was performed
with NCSS 2000 software (Statistical Solutions Ltd, Cork, Ireland).
Results
Overall Population
All 278 patients underwent clinical, hematologic, and
echocardiographic evaluation at 1, 6, and 12 months after
the operation. All patients showed a significant clinical
improvement during follow-up in terms of mean New York
Heart Association functional class. Echocardiographic
examination ruled out prosthetic dysfunction and the pres-
ence of periprosthetic leaks in all cases. Patients with a
mechanical prosthesis showed mean LDH levels at 12-
month follow-up that were significantly higher than those
of patients with a bioprosthesis (535 ± 140 U/L vs 431 ±
138 U/L, P < .001). None of the 278 patients had decom-
pensated anemia caused by intravascular hemolysis,
whereas at 12 months, mild subclinical hemolysis was iden-
tified in 49 patients, 44 (26%) with a mechanical prosthesis
and 5 (5%) with a bioprosthesis. At multivariate analysis,
independent predictors of the presence of subclinical
hemolysis at 12 months were MVR (P < .001; odds ratio
[OR], 3.4; 95% confidence interval [CI], 1.7-7.0), use of a
mechanical prosthesis (P = .002; OR, 4.9; 95% CI, 1.8-13),
and DVR (P = .02; OR, 3.9; 95% CI, 1.2-13; Table 2).
TABLE 2. Variables associated with hemolysis at univariate and multivariate analysis
Hemolysis Multivariate
Absent Present Univariate P value P value OR (95% CI)
Overall population
Mean age (y) 67 ± 9 64 ± 10 .09 >.20
Male/female (%) 85/79 15/21 .14
MVR/AVR (%) 64/89 36/11 <.001 <.001 3.4 (1.7-7.0)
DVR/single valve replacement (%) 54/84 46/16 .006 .02 3.9 (1.2-13)
Mechanical/biologic prosthesis (%) 74/95 26/5 <.001 .002 4.9 (1.8-13)
Aortic valve recipients
Mean age (y) 67 ± 9 63 ± 11 .07 >.20
Aortic peak transprosthetic gradient 20 ± 8 25 ± 7 .01 >.20
Aortic mean transprosthetic gradient 12 ± 5 15 ± 5 .03 >.20
DVR/AVR (%) 54/89 46/11 .003 >.20
Mechanical/biologic prosthesis (%) 79/98 21/2 <.001 .001 9.3 (1.6-53)
Mitral valve recipients
Male/female (%) 75/58 25/42 .17
Left ventricular ejection fraction 55 ± 5 52 ± 9 .17
Aortic peak transprosthetic gradient 9 ± 3 7 ± 3 .16
Mechanical valve recipients
Male/female (%) 80/66 20/34 .05 >.20
CM/SB prosthesis (%) 66/78 34/22 .09 .13 1.8 (0.8-3.8)
MVR/AVR (%) 63/79 37/21 .04 .05 2.3 (1.0-5.6)
DVR/AVR (%) 54/76 46/24 .08 .04 3.5 (1.0-12)
Bioprosthesis recipients
MVR/AVR (%) 77/98 23/2 .01 .007 13.6 (2.0-92)
TABLE 3. Hematologic data
1 mo 6 mo 1 y
Bioprostheses (n = 106)
Hemoglobin (g/dL) 12.9 ± 1.3 13.6 ± 1.5 13.6 ± 1.8
Reticulocytes (%) 1.6 ± 0.6 1.5 ± 0.6 1.6 ± 0.6
Presence of schistocytes – – –
LDH (U/L) 439 ± 122 424 ± 106 426 ± 113
Haptoglobin (g/L) 1.82 ± 0.99 1.53 ± 0.81 1.44 ± 0.76
Hemolysis (%) 6.3 4.7 4.7
Mechanical prostheses (n = 172)
Hemoglobin (g/dL) 12.9 ± 1.4 13.9 ± 1.6 14.0 ± 1.6
Reticulocytes (%) 1.8 ± 0.6 1.6 ± 0.5 1.6 ± 0.5
Presence of schistocytes 3 1 1
LDH (U/L) 516 ± 134 525 ± 145 535 ± 140
Haptoglobin (g/L) 0.59 ± 0.82 0.32 ± 0.49 0.30 ± 0.44
Hemolysis (%) 29.3 25.6 25.6
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Considering only patients with subclinical hemolysis at
1 year, mean levels of LDH were 593 ± 104 U/L for patients
undergoing AVR versus 654 ± 134 U/L for patients under-
going MVR (P = .05), 641 ± 134 U/L for mechanical valve
recipients versus 535 ± 75 U/L for bioprosthesis recipients
(P = .04), and 809 ± 195 U/L for patients undergoing DVR
versus 621 ± 122 U/L for patients undergoing single valve
replacement (P = .002).
In the subgroup of patients with AVR, multivariate
analysis indicated the use of a mechanical prosthesis as the
only independent predictor of subclinical hemolysis at 12
months (P = .001; OR, 9.3; 95% CI, 1.6-53; Table 2). In the
subgroup of patients with MVR, multivariate analysis was
not performed because no variables were associated with
subclinical hemolysis at 12 months with a P value of .10 or
less at univariate analysis (Table 2).
Bioprostheses
At all follow-up intervals, the majority of patients with a
bioprosthesis had hemoglobin, LDH, and haptoglobin lev-
els and reticulocyte counts within the range of normality
(Table 3). Serum LDH levels showed a small but significant
decrease during follow-up (ANOVA F = 3.1, P = .05) and
were slightly lower in patients with an aortic than in those
with a mitral bioprosthesis (421 ± 115 U/L vs 458 ± 97 U/L
at 12-month follow-up, P = .07; Figure 1). Only 5 (5%)
patients with a bioprosthesis fulfilled the criteria for
intravascular hemolysis, 2 (3%) patients with an aortic
Figure 1. Serum LDH (in units per liter) and haptoglobin (in grams per liter) distribution at 1, 6, and 12 months after
AVR and MVR with a bioprosthesis. The horizontal gray band represents the range of normality for LDH levels.
Figure 2. Serum LDH (in units per liter) and haptoglobin (in grams per liter) distribution at 1, 6, and 12 months after
AVR, MVR, and DVR with a mechanical prosthesis. The horizontal gray band represents the range of normality for LDH
levels.
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stented valve and 3 (23%) with a porcine valve in the mitral
position. None of the 15 patients with a stentless aortic bio-
prosthesis showed signs of intravascular hemolysis. At mul-
tivariate analysis, the only independent predictor of
subclinical hemolysis at 12 months was MVR (P = .007;
OR, 13.6; 95% CI, 2.0-92; Table 2).
Mechanical Prostheses
Serum LDH levels significantly increased during follow-up
(ANOVA F = 6.2, P = .002), with levels at 12-month fol-
low-up being significantly higher than those at 1-month fol-
low-up (P = .04, Bonferroni test; Table 3 and Figure 2). At
12-month follow-up, mean levels of LDH were 718 ± 192
U/L for patients undergoing DVR versus 520 ± 123 U/L for
patients undergoing single valve replacement (P < .001) and
500 ± 116 U/L for patients undergoing AVR versus 569 ±
129 U/L for patients undergoing MVR (P = .001). Serum
levels of LDH in patients with an SB were lower than those
found in patients with a CM prosthesis after AVR (450 ± 88
U/L vs 609 ± 93 U/L, P < .001), MVR (539 ± 126 U/L vs
644 ± 109 U/L, P = .01), and DVR (639 ± 170 U/L vs 844
± 167 U/L, P = .06; Figure 3). Serum haptoglobin levels
significantly decreased during follow-up (ANOVA F =
30.7, P < .001, Figure 2); the Bonferroni test showed a sig-
nificant difference between 1-month follow-up and both 6-
and 12-month follow-up (P < .001). At 12-month follow-up,
haptoglobin levels were abnormally reduced in 60% of
patients undergoing AVR, 79% of patients undergoing
MVR, and 100% of patients undergoing DVR. However,
hemoglobin levels and reticulocyte counts were approxi-
mately within the normal range, indicating that decompen-
sated anemia was not occurring in these patients.
Forty-four (26%) patients with mechanical valves ful-
filled the criteria for hemolysis: 21 after AVR, 17 after
MVR, and 6 after DVR. A difference in the frequency of
hemolysis between AVR and MVR (21% vs 37%, P = .04)
and between DVR and single valve replacement (46% vs
24%, P = .08) was found. Hemolysis was also more fre-
quent in patients with a CM (34%) than in patients with an
SB (22%, P = .09). At multivariate analysis, independent
predictors of the presence of subclinical hemolysis at 1 year
were DVR (P = .04; OR, 3.5; 95% CI, 1.0-12) and MVR (P
= .05; OR, 2.3; 95% CI, 1.0-5.6; Table 2).
Considering only patients with subclinical hemolysis at
1 year, mean levels of LDH were 809 ± 195 U/L after DVR,
599 ± 106 U/L after AVR (P < .001 vs DVR), and 633 ± 99
U/L after MVR (P = .004 vs DVR, Figure 4). Serum levels
of LDH in patients with an SB were lower than those found
in patients with a CM, irrespective of valve position (728 ±
123 U/L vs 580 ± 107 U/L, P < .001).
Discussion
Mild degrees of intravascular hemolysis are common
among patients with normally functioning prostheses.6,10-13
Absence of severe hemolysis in the present series may be
related to the use of newer-generation valves and better
methods of evaluating prosthetic valve function.
Transesophageal echocardiography is increasingly used in
the evaluation of prosthetic dysfunction and is particularly
useful in determining the site and mechanism of prosthetic
regurgitation.14 Detection of subclinical periprosthetic leaks
is important because they contribute to the degree of
intravascular hemolysis.2 Intravascular hemolysis has been
reported also in patients with dysfunctional biologic pros-
theses in the aortic, as well as the mitral, position.15,16
Experimental works with stented porcine or pericardial
prostheses have shown that turbulent shear stresses might
cause endothelial damage and sublethal or lethal damage to
Figure 3. Serum LDH (in units per liter) levels at 12 months after
AVR, MVR, and DVR with an SB or CM prosthesis. The horizontal
gray band represents the range of normality for LDH levels.
Figure 4. Serum LDH (in units per liter) and haptoglobin (in grams
per liter) levels at 12 months in patients with subclinical hemolysis
after AVR, MVR, and DVR with a mechanical prosthesis. The hori-
zontal gray band represents the range of normality for LDH levels.
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blood corpuscles.17,18 This can explain the few cases of sub-
clinical hemolysis found in our series of patients with bio-
logic prostheses. Moreover, none of the patients with a
stentless porcine aortic valve showed subclinical hemolysis,
most likely indicating a better hemodynamic performance
and flow characteristics of such devices.19,20 Intravascular
hemolysis may be found in 40% to 85% of patients with
normally functioning mechanical prostheses.1,6,10,11 Early
reports showed higher LDH levels for aortic ball valves,21
but this trend was reversed for some tilting disc valves22 and
for bileaflet valves.5,11 In the present series of patients with
a new generation of bileaflet prosthetic valves, subclinical
hemolysis was found in 26% of patients. We also observed
a greater frequency and severity of hemolysis in patients
undergoing DVR, as reported by others.10,23 Significant
LDH elevation occurs after single AVR or MVR, but it is
higher in patients undergoing MVR.
Recently, fluid-dynamic simulation models have identi-
fied distinct patterns of regurgitant flow disturbances in
patients with mitral mechanical prostheses that were associ-
ated with high shear stress and may therefore produce
hemolysis.14 This observation would indicate that low levels
of hemolysis generated by bileaflet valves are probably
caused by backflow and closing phenomena rather then for-
ward flow.24 The SB and CM prostheses are widely used,
and many reports have confirmed their excellent hemody-
namics and durability, but there are no reported studies com-
paring the incidence of hemolysis with these 2 prostheses.
The results of our study show that in the present series SB
prostheses were associated with a lower severity of hemoly-
sis than CM prostheses. Several factors may account for this,
but we believe that the peculiar design of the SB prosthesis
with the curved profile of the 2 leaflets may play an impor-
tant role. Indeed, in vitro studies have demonstrated a shorter
spatial extension of the turbulent zone in the forward flow
phase in this prosthesis when compared with prostheses with
2 flat-surface leaflets.25 Moreover, experimental studies
comparing leakage flow and shear stress within the gap flow
of different mechanical bileaflet valves have shown that the
SB prosthesis has a lower blood-damage index and hemoly-
sis than the CM prosthesis.24 Finally, we were not able to
identify any possible correlation between the frequency and
severity of intravascular hemolysis and cardiac rhythm, left
ventricular ejection fraction, prosthetic size, and transpros-
thetic peak and mean pressure gradients. Furthermore, the
low levels of hemolysis observed, particularly in mechanical
valve recipients, in the present study were of no clinical rel-
evance at 1-year follow-up, and in our opinion they should
not represent a problem in the long term.
In conclusion, in normally functioning prosthetic heart
valves subclinical hemolysis is a frequent finding that
remains stable during follow-up. A low incidence of hemoly-
sis is found in stented biologic prostheses, whereas it is
absent in stentless valves after AVR. Modifications of valve
design may contribute to a further minimization of the
occurrence of hemolysis in mechanical prostheses.
References
1. DeCesare W, Rath C, Hufnagel C. Hemolytic anemia of mechanical
origin with aortic-valve prostheses. N Engl J Med. 1965;272:1045-50.
2. Kastor JA, Akbarian M, Buckley MJ, Dinsmore RE, Sanders CA,
Scannell JG, et al. Paravalvular leaks and hemolytic anemia following
insertion of Starr-Edwards aortic and mitral valves. J Thorac Cardio-
vasc Surg. 1968;56:279-88.
3. Kloster FE. Diagnosis and management of complications of prosthetic
heart valves. Am J Cardiol. 1975;35:872-85.
4. Magilligan DJJ, Fisher E, Alam M. Hemolytic anemia with porcine
xenograft aortic and mitral valves. J Thorac Cardiovasc Surg. 1980;
79:628-31.
5. Chang H, Lin FY, Hung CR, Chu SH. Chronic intravascular hemoly-
sis after valvular surgery. J Formos Med Assoc. 1990;89:880-6.
6. Birnbaum D, Laczkovics A, Heidt M, Oelert H, Laufer G, Greve H, et
al. Examination of hemolytic potential with the On-X(R) prosthetic
heart valve. J Heart Valve Dis. 2000;9:142-5.
7. Liu JS, Lu PC, Chu SH. Turbulence characteristics downstream of
bileaflet aortic valve prostheses. J Biomech Eng. 2000;122:118-24.
8. Ellis JT, Wick TM, Yoganathan AP. Prosthesis-induced hemolysis:
mechanisms and quantification of shear stress. J Heart Valve Dis.
1998;7:376-86.
9. Nygaard H, Paulsen PK, Hasenkam JM, Kromann-Hansen O,
Pedersen EM, Rovsing PE. Quantitation of the turbulent stress distri-
bution downstream of normal, diseased and artificial aortic valves in
humans. Eur J Cardiothorac Surg. 1992;6:609-17.
10. Skoularigis J, Essop MR, Skudicky D, Middlemost SJ, Sareli P.
Frequency and severity of intravascular hemolysis after left-sided car-
diac valve replacement with Medtronic Hall and St. Jude Medical
prostheses, and influence of prosthetic type, position, size and num-
ber. Am J Cardiol. 1993;71:587-91.
11. Lillehei CW. Hemolysis and the St. Jude Medical valve. Eur J
Cardiothorac Surg. 1989;3:90-1.
12. Milano A, Guglielmi C, De Carlo M, Di Gregorio O, Borzoni G,
Verunelli F, et al. Valve-related complications in elderly patients with
biological and mechanical aortic valves. Ann Thorac Surg. 1998;
66:S82-7.
13. Ismeno G, Renzulli A, Carozza A, De Feo M, Iannuzzi M, Sante P, et
al. Intravascular hemolysis after mitral and aortic valve replacement
with different types of mechanical prostheses. Int J Cardiol.
1999;69:179-83.
14. Garcia MJ, Vandervoort P, Stewart WJ, Lytle BW, Cosgrove DM,
Thomas JD, et al. Mechanisms of hemolysis with mitral prosthetic
regurgitation. Study using transesophageal echocardiography and
fluid dynamic simulation. J Am Coll Cardiol. 1996;27:399-406.
15. Konstantopoulos K, Kasparian T, Sideris J, Voskaridou E,
Loukopoulos D. Mechanical hemolysis associated with a biopros-
thetic mitral valve combined with a calcified aortic valve stenosis.
Acta Haematol. 1994;91:164-5.
16. Brown MR, Hasaniya NW, Dang CR. Hemolytic anemia secondary to
a porcine mitral prosthetic valve leaflet dissection. Ann Thorac Surg.
1995;59:1573-4.
17. Hasenkam JM, Nygaard H, Pedersen EM, Ostergaard JH, Paulsen PK,
Johannsen G. Turbulent stresses downstream of porcine and pericar-
dial aortic valves implanted in pigs. J Card Surg. 1989;4:74-8.
18. Nygaard H, Giersiepen M, Hasenkam JM, Reul H, Paulsen PK,
Rovsing PE, et al. Two-dimensional color-mapping of turbulent shear
stress distribution downstream of two aortic bioprosthetic valves in
vitro. J Biomech. 1992;25:429-40.
19. Dumesnil JG, LeBlanc MH, Cartier PC, Metras J, Desaulniers D,
Doyle DP, et al. Hemodynamic features of the freestyle aortic bio-
prosthesis compared with stented bioprosthesis. Ann Thorac Surg.
1998;66:S130-3.
20. Silberman S, Shaheen J, Fink D, Tzivoni D, Rosenmann D, Shapira N,
et al. Comparison of exercise hemodynamics among nonstented aor-
556 The Journal of Thoracic and Cardiovascular Surgery • March 2002
Cardiopulmonary Support and Physiology Mecozzi et al
ED
ITO
RIA
L
CH
D
G
TS
A
CD
CSP
CSP
TX
tic bioprostheses, mechanical valves, and normal native aortic valves.
J Card Surg. 1998;13:412-6.
21. Myhre E, Rasmussen K, Andersen A. Serum lactic dehydrogenase
activity in patients with prosthetic heart valves: a parameter of
intravascular hemolysis. Am Heart J. 1970;80:463-8.
22. Febres-Roman PR, Bourg WC, Crone RA, Davis RCJ, Williams TH.
Chronic intravascular hemolysis after aortic valve replacement with
Ionescu-Shiley xenograft: comparative study with Bjork-Shiley pros-
thesis. Am J Cardiol. 1980;46:735-8.
23. Camishion RC, Hughes JL. Severe intravascular hemolysis after triple
valve replacement: cure by replacement of aortic and mitral valves
with porcine xenografts. Surgery. 1979;85:246-8.
24. Steegers A, Paul R, Reul H, Rau G. Leakage flow at mechanical heart
valve prostheses: improved washout or increased blood damage? J
Heart Valve Dis. 1999;8:312-23.
25. Grigioni M, Daniele C, D’Avenio G, Barbaro V. The influence of the
leaflets’ curvature on the flow field in two bileaflet prosthetic heart
valves. J Biomech. 2001;34:613-21.
Online—www.aats.org
Now you can get The Journal of Thoracic and Cardiovascular Surgery online. 
The Journal online brings you faster delivery time, easy searching of current and
back issues, links to PubMed, AATS, WTSA, and other important sites, and more. 
Visit the Journal online today.
Receive tables of contents by e-mail
To receive the tables of contents by e-mail, sign up through our Web site at 
http://www.mosby.com/jtcvs
Choose E-mail Notification
Simply type your e-mail address in the box and click the Subscribe button.
Alternatively, you may send an e-mail message to majordomo@mosby.com.
Leave the subject line blank and type the following as the body of your message: 
subscribe jtcvs_toc
You will receive an e-mail to confirm that you have been added to the mailing list. 
Note that TOC e-mails will be sent out when a new issue is posted to the Web site.
